126 related articles for article (PubMed ID: 12174677)
1. The molecular genetics of therapeutic resistance in malignant astrocytomas.
Jennings MT; Iyengar S
Am J Pharmacogenomics; 2001; 1(2):93-9. PubMed ID: 12174677
[TBL] [Abstract][Full Text] [Related]
2. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
[TBL] [Abstract][Full Text] [Related]
3. ATAD 3A and ATAD 3B are distal 1p-located genes differentially expressed in human glioma cell lines and present in vitro anti-oncogenic and chemoresistant properties.
Hubstenberger A; Labourdette G; Baudier J; Rousseau D
Exp Cell Res; 2008 Sep; 314(15):2870-83. PubMed ID: 18639545
[TBL] [Abstract][Full Text] [Related]
4. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
6. p53 and response to chemotherapy and radiotherapy.
Ruley HE
Important Adv Oncol; 1996; ():37-56. PubMed ID: 8791127
[No Abstract] [Full Text] [Related]
7. IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.
Becher OJ; Peterson KM; Khatua S; Santi MR; MacDonald TJ
J Child Neurol; 2008 Oct; 23(10):1205-13. PubMed ID: 18952587
[TBL] [Abstract][Full Text] [Related]
8. Does P-glycoprotein play a role in clinical resistance of malignant astrocytoma?
Ashmore SM; Thomas DG; Darling JL
Anticancer Drugs; 1999 Nov; 10(10):861-72. PubMed ID: 10630353
[TBL] [Abstract][Full Text] [Related]
9. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
[TBL] [Abstract][Full Text] [Related]
10. Current concepts in neuro-oncology: the cell cycle--a review.
Dirks PB; Rutka JT
Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
[TBL] [Abstract][Full Text] [Related]
11. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
[TBL] [Abstract][Full Text] [Related]
12. The cell cycle: accelerators, brakes, and checkpoints.
Ivanchuk SM; Rutka JT
Neurosurgery; 2004 Mar; 54(3):692-9; discussion 699-700. PubMed ID: 15028146
[TBL] [Abstract][Full Text] [Related]
13. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.
Nutt CL; Noble M; Chambers AF; Cairncross JG
Cancer Res; 2000 Sep; 60(17):4812-8. PubMed ID: 10987291
[TBL] [Abstract][Full Text] [Related]
15. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
16. Genetics of astrocytic tumor progression.
Mikkelsen T
Mol Genet Med; 1993; 3():69-94. PubMed ID: 8220164
[No Abstract] [Full Text] [Related]
17. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.
Kirla R; Salminen E; Huhtala S; Nuutinen J; Talve L; Haapasalo H; Kalimo H
J Neurooncol; 2000; 46(1):71-80. PubMed ID: 10896207
[TBL] [Abstract][Full Text] [Related]
18. Advances in the biology of astrocytomas.
Guha A; Mukherjee J
Curr Opin Neurol; 2004 Dec; 17(6):655-62. PubMed ID: 15542973
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors.
Rathore A; Kamarajan P; Mathur M; Sinha S; Sarkar C
Pathol Oncol Res; 1999; 5(1):21-7. PubMed ID: 10079373
[TBL] [Abstract][Full Text] [Related]
20. The retinoblastoma gene is involved in malignant progression of astrocytomas.
Henson JW; Schnitker BL; Correa KM; von Deimling A; Fassbender F; Xu HJ; Benedict WF; Yandell DW; Louis DN
Ann Neurol; 1994 Nov; 36(5):714-21. PubMed ID: 7979217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
